Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Inclusion Criteria:

1. 18 - 80 years, male or female;
2. Clinically diagnosed as acute anterior ischemic stroke, artery occlusion occurred atthe terminal of the intracranial carotid artery, T-shaped bifurcation or M1 segment ofthe middle cerebral artery;
3. Within 24 hours of stroke onset;
4. Eligible for other imaging indications for bridging therapy or direct mechanicalthrombectomy: ASPECTS ≥6 certified by the latest brain CT imaging; Patients within 6-16 hours afterstroke onset should meet the mismatch criteria, which was defined as infarction corevolume <70 ml, mismatch ratio ≥1.8 and the ischemic volume > 15 ml (DEFUSE-3Criteria); or NIHSS score ≥ 10 with infarction -core volume < 31 cm3, or NIHSS score ≥ 20 with infarction core volume ≤ 51 cm3 (DAWN Criteria); Patients within 16-24 hoursafter stroke onset should meet the mismatch criteria, which was defined as NIHSS score ≥ 10 with infarction-core volume < 31 cm3, or NIHSS score ≥ 20 with infarction-corevolume ≤ 51 cm3 (DAWN Criteria);
5. Planned to receive bridging therapy (endovascular therapy after intravenous alteplase)or direct endovascular therapy;
6. Pre-morbid modified Rankin Scale ≤1;
7. 6 ≤ NIHSS ≤ 25 before endovascular therapy;
8. Signed informed consent from subjects or legally authorized representatives

Exclusion Criteria:

1. CT indicates intracranial hemorrhagic diseases, such as hemorrhagic stroke, subduralhematoma, ventricular hemorrhage, or subarachnoid hemorrhage, etc.;
2. Had been given any intravenous thrombolytic drug other than alteplase before bridgingtherapy;
3. Hypersensitive to edaravone, (+)-2- dexborneol or auxiliary materials;
4. Prior receipt of edaravone or any other neuroprotective drugs;
5. History of congenital or acquired hemorrhagic disease, coagulation factor deficiencydisease, or thrombocytopenic disease, etc.;
6. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg afterantihypertensive treatment;
7. Serum alanine aminotransferase (ALT) or aspartate transaminase (AST) elevates over 3times of upper limit of normal;
8. Recent or current serum creatinine is known to exceed 1.5 times the upper limit ofnormal, or estimated glomerular filtration rate (eGFR) < 60 mL/min;
9. Pregnancy, lactation, or planned pregnancy within 90 days;
10. Those who cannot complete informed consent or follow-up treatment due to severe mentaldisorder or dementia;
11. Those with a malignant tumor, severe systemic diseases, or predict survival time <90days;
12. Participate in another interventional clinical study within 30 days beforerandomization or participate in another interventional clinical study.